Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic plc (MDT) CEO Geoffrey Martha on Q2 2022 Results - Earnings Call Transcript

Adobe

ASML Hld

Global Payments

Matterport

Shopify

7 Top Tech Stocks to Buy Despite Recent Tapering Concerns

Medtronic (MDT) cuts revenue growth guidance for the full year on the projection of a severe pandemic impact to continue through the rest of the year.

Medtronic's (MDT) Q2 Earnings Beat, Revenues Lag Estimates

Medtronic Plc's (NYSE: MDT) Q2 FY22 sales of $7.85 billion increased 3% Y/Y as reported and 2% on an organic basis, missing the consensus of $7.96 billion. Q2 adjusted EPS of $1.32 increased 30% from $1.02 a year ago, surpassing the analyst consensus of $1.29.

Medtronic Q2 Sales Hit By By Labor Shortage, COVID-19; Expects Lower Sales Growth Rate For FY22

The maker of medical devices beat expectations for earnings, but slashed its outlook for sales growth for the remainder of this fiscal year.

Medtronic Misses on Sales and Cuts Outlook—It Isn't All Bad News

Shares of Medtronic PLC MDT, -0.28% dropped 1.2% toward an eight-month low in premarket trading Tuesday, after the medical technology company beat fiscal second-quarter profit expectations but missed on revenue, citing the negative impact of the COVID-19 pandemic resurgence and healthcare staffing challenges on medical procedure volumes. Net income for the quarter to Oct. 29 nearly tripled to $1.31 billion, or 97 cents a share, from $489 million, or 36 cents a share, in the year-ago period.

Medtronic stock drops toward 8-month low after revenue miss and lowered full-year growth outlook

DUBLIN, Nov. 23, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021. Key Highlights Revenue of $7.8 billion increased 3% reported and 2% organic GAAP diluted EPS of $0.97; non-GAAP diluted EPS of $1.32 Reiterates full year EPS guidance "As our markets recover, Medtronic is one of the best positioned companies in healthcare.

Medtronic Reports Second Quarter Fiscal 2022 Financial Results

Medtronic stock is scheduled to report its fiscal second-quarter results on Tuesday, Nov 23. We expect Medtronic to likely post revenues and earnings largely in-line with the consensus estimates.

What To Expect From Medtronic's Q2?

XPeng

Zoom Video

Of the three companies we previewed earlier this week that reported quarterly results after markets closed Thursday, Applied Materials missed estimates on both revenue and profits while Workday and Ross Stores beat on both.

Earnings Previews: Medtronic, Xpeng, Zoom Video

Through Medtronic's (MDT) second-quarter months, the market continues return to normalcy on mass vaccine rollouts in spite of COVID-19 resurgence.

Medtronic (MDT) to Report Q2 Earnings: What's in the Offing?

Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.

Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance

DUBLIN, Nov. 15, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam™ Small Bowel 3 system for remote endoscopy procedures. The PillCam™ SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, a combination intended to ensure both timely and accurate results for patients from the comfort of their homes.

Medtronic announces 510(k) clearance for PillCam™ Small Bowel 3 @HOME endoscopy procedure

Four external appointments include new digital innovation leader, head of global strategy and two Operating Unit President roles within the Neuroscience Portfolio DUBLIN, Nov. 15, 2021   /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced four executive appointments to further its commitment to become the global leader in healthcare technology. Bob Hopkins , head of global strategy, effective today.

Medtronic taps top digital and healthcare technology leaders to drive company transformation

DUBLIN, Nov. 15, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its inclusion in the Dow Jones® Sustainability World Index (DJSI World) as one of the world's leading companies for sustainability. The DJSI World Index includes a select group of companies based on their performance across a variety of sustainability criteria, including economic performance, environmental stewardship, social responsibility, and corporate governance.

Medtronic named to the Dow Jones Sustainability World Index

Visa

These income stocks also make for good recovery plays.

2 Dividend Stocks to Buy on the Dip

In the latest trading session, Medtronic (MDT) closed at $122.29, marking a -0.59% move from the previous day.

Medtronic (MDT) Dips More Than Broader Markets: What You Should Know

DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2022 on Tuesday, November 23, 2021. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its second quarter of fiscal year 2022

DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its ambition to achieve net zero carbon emissions by fiscal year (FY) 2045 across its operations and value chain (scopes 1, 2, and 3) to accelerate efforts to combat climate change. The announcement comes during the 2021 United Nations Climate Change Conference (COP 26), where world leaders are focusing on collectively cutting greenhouse gas (GHG) emissions and limiting global warming to 1.5 degrees Celsius compared to pre-industrial levels.

Medtronic announces 2045 net zero emissions ambition to combat climate change

Medtronic plc (NYSE: MDT) announced early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system for mitral valve regurgitation (MR) utilizing the transfemoral access route.  Data from the first 15 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke, a median procedure time of 46 minutes, and none/trace MR in all implanted patients at 30 days.

Medtronic's Intrepid Valve Eliminates Mitral Regurgitation At 30 Days, Study Shows

Transfemoral access added into landmark APOLLO Pivotal Trial following IDE approval from FDA DUBLIN and ORLANDO, Fla., Nov. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today presented early data for its self-expanding Intrepid™ transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation (MR) utilizing the transfemoral access route.

Medtronic announces early data for the Intrepid™ transcatheter mitral valve replacement (TMVR) system using new transfemoral delivery system

Medtronic plc (NYSE: MDT) presented five-year clinical data for CoreValve and Evolut transcatheter aortic valve implantation (TAVI) platforms at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference. The trial evaluated two early valve generations across various valve sizes in 864 intermediate-risk symptomatic severe aortic stenosis patients.

Medtronic Touts 5-Year Data Of Self-Expanding TAVR Platform

TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late Breaking Clinical Trial at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation.

Medtronic self-expanding TAVR platform shows excellent longer-term performance at five years in SURTAVI Trial

New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO, Fla., Nov. 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced findings from a new study of the Patient Preferences for the Treatment of Hypertension.

Medtronic study shows patients with high blood pressure are interested in an interventional procedure treatment option

AbbVie

Aflac

Franklin Resources

Cardinal Health

Hormel Foods

Johnson & Johnson

McKesson

NextEra Energy

Procter & Gamble

V.F.

Walgreens

S&P 500 dividend aristocrats possess pretty safe dividends. All 65 of them have paid out higher disbursements for at least 25 straight years. We decided to put together our Buy list for the top six to purchase right now.

The Dividend Aristocrat 6-Pack Buy List

SAN FRANCISCO, Nov. 2, 2021 /PRNewswire/ --  Rune Labs , a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases, and Medtronic plc  (NYSE:MDT), a global leader in healthcare technology, today announced a new project designed to better understand the effects of neurostimulation in order to improve patient care. This collaboration will use Rune's proprietary software platform to integrate, analyze, and display data captured from Medtronic's Percept™ PC Neurostimulator, along with data from the StrivePD Apple Watch application and other sources.

News for Medtronic Stock (MDT)